Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and ...
Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing ...
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, ...
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsMarDee Haring-Layton - Chief Accounting ...
FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies.
A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...
The smart thermometer performs a check-up on your body temperature, cardiac, and pulmonary health in less than a minute.
Thousands of abortions in South Carolina were done through medication in 2024. South Carolina lawmakers, state leaders and ...
The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...
TipRanks on MSN
FDA Opens the Door for AI in Clinics, Priming Market for $2.7T Digital Health Wave by 2035
Vancouver, Canada, November 4th, 2025, FinanceWire USA News Group News Commentary – Healthcare’s embrace of AI is moving from ...
This is read by an automated voice. Please report any issues or inconsistencies here. A rare-disease patient questions what drives research costs behind $41,000-per-month medication, even before FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results